- Home
- VYNE vs KYNB Comparison
VYNE vs KYNB Comparison
Compare VYNE & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VYNE | KYNB |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 27.1M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | VYNE | KYNB |
|---|---|---|
| Price | $0.79 | $7.04 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 535.6K | 15.6K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $6.32 |
| 52 Week High | $1.60 | $9.58 |
Technical Indicators
Market Signals| Indicator | VYNE | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 75.24 | 48.45 |
| Support Level | $0.56 | $7.04 |
| Resistance Level | N/A | $7.41 |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 97.42 | 9.03 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.